News | July 11, 2025
Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Subscribe To Our Newsletter & Stay Updated
